MeSH D016491 - peripheral vascular diseases
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D016491:Â
Peripheral vascular diseases
D004916:Erythromelalgia
0 Companies
0 Drugs
Success rate
D010689:Phlebitis
0 Companies
0 Drugs
Success rate
D011928:Raynaud disease
D018438:Blue toe syndrome
0 Companies
0 Drugs
Success rate
D054068:Livedo reticularis
0 Companies
0 Drugs
Success rate
D058729:Peripheral arterial disease
D062108:May-thurner syndrome
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Cilostazol | Cilostazol |  | 2005-03-01 |  |  |
| Clopidogrel | Clopidogrel Teva (hydrogen sulphate) |  | 2009-07-27 |  |  | |
| Clopidogrel | Clopidogrel Teva Pharma (previously Clopidogrel HCS) |  | 2009-09-21 |  |  | |
| Clopidogrel | Clopidogrel ratiopharm |  | 2015-02-18 |  |  | |
| Niacin | Niacin |  | 1982-01-01 |  |  | |
| Clopidogrel | Clopidogrel Teva Generics B.V |  | 2010-10-28 |  |  | |
| Clopidogrel | Clopidogrel Teva Pharma B.V |  | 2011-06-16 |  |  | |
| Rising Pharmaceuticals | Cilostazol | Cilostazol |  | 2006-04-20 |  |  |
| Niacin | Niacin |  | 2019-02-22 |  |  | |
| Mylan | Clopidogrel | Clopidogrel DURA |  | 2009-07-21 |  |  |
| Roche | Folic acid, Dexpanthenol, Ascorbic acid, Cyanocobalamin, Ergocalciferol, Vitamin a, Biotin, Niacinamide, Pyridoxine, Riboflavin, Thiamine | Berocca Pn |  | 1985-10-10 |  |  |
| Chartwell Pharmaceuticals | Niacin | Niacin |  | 2014-03-20 |  |  |
| Cilostazol | Cilostazol |  | 2012-09-24 |  |  | |
| Sandoz | Folic acid, Dexpanthenol, Ascorbic acid, Cyanocobalamin, Vitamin a, Alpha-tocopherol, Biotin, Cholecalciferol, Niacinamide, Pyridoxine, Riboflavin, Thiamine, Tocopherol | Infuvite |  | 2000-05-18 |  |  |
| Niacin | Niacin |  | 1982-01-01 |  |  | |
| AbbVie | Niacin | Niaspan Titration Starter Pack |  | 1997-07-28 |  |  |
| AstraZeneca | Ticagrelor | Brilique |  | 2010-12-03 |  |  |
| Ticagrelor | Possia |  | 2010-12-03 |  |  |
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
57%4/7
Phase 2
65%13/20
Phase 3
35%12/34
Approved: 6Overall Success rate: 13%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use